Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cassava Sciences, Inc. - Common Stock (NQ:SAVA)

3.260 -0.020 (-0.61%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cassava Sciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
38 39 Next >
Shareholders that Lost Money on Cassava Sciences, Inc. (SAVA) Should Contact Levi & Korsinsky About Pending Class Action - SAVA
Via ACCESSWIRE
Cassava Sciences, Inc. Class Action: Levi & Korsinsky Reminds Cassava Sciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025 - SAVA
Via ACCESSWIRE
CASSAVA SCIENCES SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Cassava Sciences, Inc. - SAVA
From Kahn Swick & Foti, LLC
Via Business Wire
Cassava Sciences, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your Rights - SAVA
Via ACCESSWIRE
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 10, 2025 in Cassava Sciences, Inc. Lawsuit - SAVA
Via ACCESSWIRE
Unpacking the Latest Options Trading Trends in Cassava Sciences
 
Via Benzinga
Shareholders of Cassava Sciences, Inc. Should Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your Rights - SAVA
Via ACCESSWIRE
February 10, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against SAVA
Via ACCESSWIRE
Shareholders that Lost Money on Cassava Sciences, Inc. (SAVA) Should Contact Levi & Korsinsky about Pending Class Action - SAVA
Via ACCESSWIRE
Investors in Cassava Sciences, Inc. Should Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your Rights - SAVA
Via ACCESSWIRE
Rosen Law Firm Urges Cassava Sciences, Inc. (NASDAQ: SAVA) Stockholders with Large Losses in Excess of $100K to Contact the Firm for Information About Their Rights
From The Rosen Law Firm, P.A.
Via Business Wire
Cassava Sciences, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - SAVA
Via ACCESSWIRE
SAVA LAWSUIT ALERT: Levi & Korsinsky Notifies Cassava Sciences, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
Via ACCESSWIRE
Top Biotech Short Squeeze Stocks
Investing in biotechnology stocks offers a unique opportunity for individuals looking to gain exposure to one of the most dynamic and innovative sectors of the market. 
Via Talk Markets
Topics Stocks / Equities
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
S&P 500, Nasdaq Hit Record Highs To Start December
Stocks are a mixed bag this afternoon, with the S&P 500 Index and Nasdaq Composite earlier touching fresh record highs as the latter jumps triple digits. 
Via Talk Markets
Topics Stocks Stocks / Equities
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Benzinga Bulls And Bears: Amazon, Tesla, Rivian, Palantir And How Dogecoin Helped Low-Income Families Achieve Homeownership
Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories. 
Via Benzinga
This Goldman Sachs Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
 
Via Benzinga
Cassava Sciences, Zoom, Kohl's, Rivian, Tesla: Why These 5 Stocks Are On Investors' Radars Today
SAVA, ZM, KSS, RIVN, TSLA were among the trending stocks among investors on Monday Nov. 25, 2024. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Gold Down Over 3%; Rigetti Computing Shares Spike Higher
 
Via Benzinga
Crude Oil Down 3%; Chicago Fed National Activity Index Falls In October
 
Via Benzinga
Topics Economy
'Pharma Bro' Martin Shkreli Tells Investors To 'Short SAVA,' Stock Falls Over 80% After Phase 3 Update
Pharma bro Martin Shkreli predicted Cassava Sciences stock would fall and the company would miss primary endpoints for its Phase 3 trial. 
Via Benzinga
Dow Surges Over 300 Points; Bath & Body Works Posts Upbeat Earnings
 
Via Benzinga
Topics Stocks
Cassava Sciences Alzheimer's Drug Fails To Hit Primary Goal In Pivotal Study, Pharma Halts Late-Stage Studies
Cassava Sciences' stock fell after Phase 3 simufilam trial failed to meet key endpoints, prompting the discontinuation of its Alzheimer's studies. 
Via Benzinga
Cassava Sciences Plummets 85% After Embattled Alzheimer's Drug Flops
The company tested simufilam in patients with mild-to-moderate Alzheimer's disease. 
Via Investor's Business Daily
Cassava Sciences, Biohaven And Other Big Stocks Moving Lower In Monday's Pre-Market Session
 
Via Benzinga
Cassava Sciences Topline Phase 3 Data Did Not Meet Co-Primary Endpoints
From Cassava Sciences, Inc.
Via GlobeNewswire
Cassava Sciences to Hold Corporate Update on November 25th
Webcast planned for Monday, November 25th at 8:00 AM ET 
From Cassava Sciences, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
38 39 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.